{"id":448876,"date":"2024-01-04T06:00:00","date_gmt":"2024-01-04T11:00:00","guid":{"rendered":"https:\/\/platohealth.ai\/novo-nordisk-enlists-two-flagship-biotechs-to-develop-obesity-mash-drugs\/"},"modified":"2024-01-04T07:08:26","modified_gmt":"2024-01-04T12:08:26","slug":"novo-nordisk-enlists-two-flagship-biotechs-to-develop-obesity-mash-drugs","status":"publish","type":"post","link":"https:\/\/platohealth.ai\/novo-nordisk-enlists-two-flagship-biotechs-to-develop-obesity-mash-drugs\/","title":{"rendered":"Novo Nordisk enlists two Flagship biotechs to develop obesity, MASH drugs","gt_translate_keys":[{"key":"rendered","format":"text"}]},"content":{"rendered":"
<\/div>\n

N<\/span><\/span>ovo Nordisk may already have one blockbuster obesity drug in its portfolio, but the Danish drugmaker has actively begun searching out others, including through a new partnership announced Thursday.<\/p>\n

Novo Nordisk will work with Omega Therapeutics, a startup founded by venture creation firm Flagship Pioneering, to develop a genetic editing treatment for obesity. The pharmaceutical company said Thursday that it has also signed a deal with Flagship-founded startup Cellarity to develop a new medicine for the fatty liver disease MASH, formerly known as NASH<\/a>.<\/p>\n

\n

advertisement<\/p>\n<\/div>\n

These are the first two deals announced under a collaboration agreement Flagship and Novo Nordisk struck in 2022.<\/p>\n

\n
\n
\n

\n\t\t\t\t\t\tGet unlimited access to award-winning journalism and exclusive events.\t\t\t\t\t<\/p>\n

\t\t\t\t\tSubscribe<\/a>\n\t\t\t\t\t\t\t\t\t<\/div>\n<\/p><\/div>\n<\/p><\/div>\n